EU/3/19/2191

About

On 21 August 2019, orphan designation EU/3/19/2191 was granted by the European Commission to Granzer Regulatory Consulting & Services, Germany, for relacorilant for the treatment of pancreatic cancer.

Key facts

Active substance
Relacorilant
Disease / condition
Treatment of pancreatic cancer
Date of first decision
21/08/2019
Outcome
Positive
EU designation number
EU/3/19/2191

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Granzer Regulatory Consulting & Services
Kistlerhofstrasse 172c
81379 Munich
Germany
Tel: + 49 89 780 68980
E-mail: contact@granzer.biz

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating